Review Article

Clinical Practice of Hepatorenal Syndrome: A Brief Review on Diagnosis and Management

. Rendy
Kalideres General Hospital, Indonesia
* Corresponding author
. Febyan
Metro Jababeka Hospital, Indonesia
Krisnhaliani Wetarini
Garbamed Hospital, Indonesia
DOI icon 10.24018/ejmed.2021.3.2.743

Read Counter
3734

Downloads
2631

Citations

Share

Article Sidebar

Submitted 2021-02-26
Published 2021-03-23

Read counter = 3734 times

Table of Contents

Article Main Content

The hepatorenal syndrome is one of various potential causes of acute kidney injury in patients with decompensated liver disease. Hepatorenal syndrome is diagnosed based on reducing kidney function without any evidence of intrinsic kidney disease, including proteinuria, hematuria, or abnormal kidney ultrasonography. Clinically, hepatorenal syndrome is divided into two types named type 1 and type 2. The most favorable therapy for HRS cases is liver transplantation; however, only a few undergo this procedure due to the high mortality. Other modalities for hepatorenal syndrome therapy are pharmacology and non-pharmacology approaches. The purpose of management HRS is to optimize and stabilize the patient until an organ transplant available. This review aims to discuss the underlying pathophysiology and demonstrate the diagnostic approach of hepatorenal syndrome to determine the most appropriate therapeutic measures in clinical practice. The clinicians must be aware of management principles of hepatorenal syndrome to improve the quality of care for patients and optimize the clinical conditions.

Keywords: Hepatorenal syndrome, diagnosis, management, clinical approach

References

  1. P. Angeli and C. Merkel. “Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.” Journal of Hepatology, vol. 48, suppl. 1, pp. S93-103, 2008.
    DOI  |   Google Scholar
  2. P.T. Pham, P.C. Pham, A. Rastogi, et al. “Review article: current management of renal dysfunction in the cirrhotic patient.” Alimentary Pharmacology & Therapeutics, vol. 21, no. 8 pp. 949-961, 2005.
    DOI  |   Google Scholar
  3. G.W. Neff, C.W. Duncan, E.R. Schiff. “The current economic burden of cirrhosis.” Gastroenterology & Hepatology, vol. 7, no. 10, pp. 661-671, 2011.
     Google Scholar
  4. S. Scaglione, S. Kliethermes, G. Cao, et al. “The epidemiology of cirrhosis in the United States: a population-based study.” Journal of Clinical Gastroenterology, vol. 49, no. 8, pp. 690-69, 2015.
    DOI  |   Google Scholar
  5. GBD 2013 Mortality and Causes of Death Collaborators. “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.” Lancet, vol. 385, no. 9963, pp. 117-171, 2015.
    DOI  |   Google Scholar
  6. W.A. Zatoński, U. Sulkowska U, M. Mańczuk, et al. “Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe.” European Addiction Research, vol. 16, pp. 193-201, 2010.
    DOI  |   Google Scholar
  7. F. Salerno, A. Gerbes, P. Ginès, et al. “Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.” Gut, vol. 56, no. 9 pp. 1310-1318, 2007.
     Google Scholar
  8. F. Salerno, M. Cazzaniga, G. Gobbo. “Pharmacological treatment of hepatorenal syndrome: a note of optimism.” Journal of Hepatology vol. 47, no. 5, pp. 729-731, 2007.
    DOI  |   Google Scholar
  9. American Association for the Study of Liver Diseases. “Management of adult patients with ascites due to cirrhosis: update 2012.” American Association for the Study of Liver Diseases, pp. 1-96, 2012.
     Google Scholar
  10. R. Amathieu, A. Al-Khafaji, F.E. Sileanu, et al. “Significance of oliguria in critically ill patients with chronic liver disease.” Hepatology, vol. 66, pp. 1592-1600, 2017.
    DOI  |   Google Scholar
  11. V. Arroyo, C. Terra, P. Ginès. “Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.” Journal of Hepatology, vol. 46, no. 5, pp. 935-946, 2007.
    DOI  |   Google Scholar
  12. E.A. Tsochatzis, J. Bosch, A.K. Burroughs. “Liver cirrhosis.” Lancet, vol. 383, no. 9930, pp. 1749-1761, 2014.
    DOI  |   Google Scholar
  13. C. Francoz, F. Durand, J.A. Kahn, et al. “Hepatorenal syndrome.” Clinical journal of the American Society of Nephrology: CJASN, vol. 14, no. 5, pp. 774-781, 2019.
    DOI  |   Google Scholar
  14. P. Balzaretti. “Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis.” Italian Journal of Emergency Medicine, vol. 9, no. 1, pp. 49-51, 2020.
    DOI  |   Google Scholar
  15. P. Angeli, P. Ginès, F. Wong, et al. “Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.” Journal of Hepatology, vol. 62, pp. 968-974, 2015.
    DOI  |   Google Scholar
  16. V. Arroyo, P. Ginès, A.L. Gerbes, et al. “Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.” Hepatology, vol. 23, no. 1, pp. 164-176, 1996.
    DOI  |   Google Scholar
  17. P.L. Bittencourt, A.Q. Farias, C. Terra. “Renal failure in cirrhosis: emerging concepts.” World Journal of Hepatology, vol. 7, no. 21, pp. 2336-2343, 2015.
    DOI  |   Google Scholar
  18. E. Rodriguez, G.H. Pereira, E. Sola, et al. “Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.” Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol. 21, no. 11, pp. 1347-1354, 2015.
    DOI  |   Google Scholar
  19. V. Bodh, B. Sharma, R. Sharma. “Hepatorenal syndrome: a review into changing definition, diagnostic criteria, pathophysiology, and management.” CHRISMED Journal of Health and Research, vol. 7, no. 2, pp. 83-89, 2020.
    DOI  |   Google Scholar
  20. T.D. Boyer, A.J. Sanyal, G. Garcia-Tsao, et al. “Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.” Journal of Hepatology, vol. 55, no. 2, pp. 315-321, 2011.
    DOI  |   Google Scholar
  21. C. Fagundes, M.N. Pepin, M. Guevara. “Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.” Journal of Hepatology, vol. 57, no. 2, pp. 267-273, 2012.
    DOI  |   Google Scholar
  22. J.M. Belcher. “Acute kidney injury in liver disease: role of biomarkers.” Advances in Chronic Kidney Disease, vol. 22, no. 5, pp. 368-375, 2015.
    DOI  |   Google Scholar
  23. A.A. Alsaad and H.M. Wadei. “Fractional excretion of sodium in hepatorenal syndrome: clinical and pathological correlation.” World Journal of Hepatology, vol. 8, no. 34, pp. 1497-1501, 2016.
    DOI  |   Google Scholar
  24. A. Cardenas and V. Arroyo. “Hepatorenal syndrome.” Annals of Hepatology, vol. 2, no. 1, pp. 23-29, 2003.
    DOI  |   Google Scholar
  25. F.J. Gifford, J.R. Morling, J.A. Fallowfield. “Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.” Alimentary Pharmacology & Therapeutics, vol. 45, no. 5, pp. 593-603, 2017.
    DOI  |   Google Scholar
  26. C. Sole, E. Pose, E. Sola, et al. “Hepatorenal syndrome in the era of acute kidney injury.” Liver International, vol. 38, no. 11, pp. 1891-1901, 2018.
    DOI  |   Google Scholar
  27. S. Piano, H.H. Schmidt, X. Ariza, et al. “Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients with Hepatorenal Syndrome.” Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of The American Gastroenterological Association, vol. 16, no. 11, pp. 1792-1800, 2018.
    DOI  |   Google Scholar
  28. M. Cavallin, P.S. Kamath, M. Merli, et al. “Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.” Hepatology, vol. 62, no. 2, pp. 567-574, 2015.
    DOI  |   Google Scholar
  29. L. Wang, Y. Long, K.X. Li, et al. “Pharmacological treatment of hepatorenal syndrome: a network meta-analysis.” Gastroenterology Report, vol.8, no. 2, pp. 111-118, 2020.
    DOI  |   Google Scholar
  30. J. Fernández, M. Navasa, R. Planas, et al. “Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.” Gastroenterology, vol. 133, no. 3, pp. 818-824, 2007.
    DOI  |   Google Scholar
  31. A.F. Carrion and P. Martin P. “Renal dysfunction in cirrhotic patients.” The American Journal of Gastroenterology, vol. 114, no. 9, pp. 1407-1410, 2019.
    DOI  |   Google Scholar
  32. S. Mitzner. “Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: results of a prospective, randomized, controlled clinical trial.” Liver Transplant, vol.6, pp. 277-286, 2000.
    DOI  |   Google Scholar
  33. R. Bañnares, F. Nevens, F.S. Larsen, et al. “Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.” Hepatology, vol. 57, no. 3, pp. 1153-1162, 2013.
     Google Scholar
  34. European Association for the Study of the Liver and European Association for the Study of the Liver. “EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.” Journal of Hepatology, vol. 69, no. 2, pp. 406-460, 2018.
     Google Scholar
  35. T. Song, M. Rossle, F. He, et al. “Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: a systematic review and meta-analysis.” Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 50,4 (2018): 323-330.
    DOI  |   Google Scholar
  36. P. Charilaou, K. Devani, R. Petrosyan, et al. “Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients.” Digestive Diseases and Sciences, vol. 65, no. 11, pp. 3378-3388, 2020.
    DOI  |   Google Scholar
  37. M. Martin-Llahi, M. Guevara, A. Torre, et al. “Prognostic importance of the cause of renal failure.” Gastroenterology, vol. 140, no. 2, pp. 488-496, 2011.
    DOI  |   Google Scholar
  38. P. Palevsky, J. Zhang, T. O’Connor, et al. “Intensity of renal support in critically ill patients with acute kidney injury.” New England Journal of Medicine, vol. 359, pp. 7-20, 2008.
    DOI  |   Google Scholar
  39. European Association for the study of the liver. “EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.” Journal of Hepatology, vol. 53, no. 3, pp. 397-417, 2010.
    DOI  |   Google Scholar
  40. Y. Chang, Q.Y. Liu, Q. Zhang, et al. “Role of nutritional status and nutritional support in outcome of hepatitis B virus-associated acute-on-chronic liver failure.” World Journal of Gastroenterology, vol. 26, no. 29, pp. 4288-4301, 2020.
    DOI  |   Google Scholar
  41. A. O’Brien and R. Williams. “Nutrition in end-stage liver disease: principles and practice.” Gastroenterology, vol. 134, pp. 1729-1740, 2008.
    DOI  |   Google Scholar
  42. J.G. Park, W.Y. Talk, S.Y. Park, et al. “Effects of branched-chain amino acid (BCAAs) supplementation on the progression of advanced liver disease: a Korean nationwide, multicenter, prospective, observational, cohort study.” Nutrients, vol. 12, pp. 1-11, 2020.
    DOI  |   Google Scholar
  43. J.R. Ospina and J.C. Restrepo. “Pathophysiology, diagnosis and management of hepatorenal syndrome.” Revista Colombiana de Gastroenterologia, vol. 31, no. 2, pp. 141-147, 2016.
    DOI  |   Google Scholar
  44. J.G. Acevedo and M.E. Cramp. “Hepatorenal syndrome: update on diagnosis and treatment.” World Journal of Hepatology, vol. 9, no. 6, pp. 293-299, 2017.
    DOI  |   Google Scholar
  45. P. Angeli, G. Garcia-Tsao, M.K. Nadim, et al. “News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.” Journal of Hepatology, vol. 71, no. 4, pp. 811-822, 2019.
    DOI  |   Google Scholar
  46. J. Chmielewski, R.J. Lewandowski, H. Maddur. “Hepatorenal syndrome: physiology, diagnosis, and management.” Seminars in Interventional Radiology, vol. 3, no. 35, pp. 194-197, 2018.
    DOI  |   Google Scholar
  47. C. Alessandria, O. Ozdogan, M. Guevara, et al. “MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.” Hepatology, vol. 41, no. 6, pp. 1282-1289, 2005.
    DOI  |   Google Scholar
  48. B. Appenrodt, J. Zielinski, K.A. Brensing, et al. “Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis. European Journal of Gastroenterology & Hepatology, vol. 21, no. 12, pp.1428-1432, 2009.
    DOI  |   Google Scholar
  49. C. Pant, B.S. Jani, M. Desai, et al. “Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide Inpatient Sample 2002-2012.” Journal of Investigative Medicine: The Official Publication of The American Federation for Clinical Research, vol. 64, no. 1, pp. 33-38, 2016.
    DOI  |   Google Scholar
  50. N. Goldaracena, M. Marquez, N. Selzner, et al. “Living vs. deceased donor liver transplantation provides comparable recovery of renal function in patients with hepatorenal syndrome: a matched case-control study.” American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 14, no. 12, pp. 2788-2795, 2014.
    DOI  |   Google Scholar
  51. V. Arroyo and J. Fernández. “Management of hepatorenal syndrome in patients with cirrhosis.” Nature Reviews Nephrology, vol. 7, no. 9, pp. 517-526, 2011.
    DOI  |   Google Scholar
  52. F. Salerno, R.J. Navickis, M.M. Wilkes. “Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials.” Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of The American Gastroenterological Association, vol. 11, no. 2, pp. 123-130, 2013.
    DOI  |   Google Scholar
  53. P. Tyagi, P. Sharma, B.C. Sharma, et al. “Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo.” European Journal of Gastroenterology & Hepatology, vol. 23, no. 3, pp. 210-217, 2011.
    DOI  |   Google Scholar